Home / World News / Boulder’s Array BioPharma spins out subsidiary to develop rare-disease drugs – The Denver Post

Boulder’s Array BioPharma spins out subsidiary to develop rare-disease drugs – The Denver Post

Associate scientist Robyn Hamor works on an enzyme-linked immunosorbent assay at Array BioPharma in Boulder in 2015.

Daily Camera, file photo

Associate scientist Robyn Hamor works on an enzyme-linked immunosorbent assay at Array BioPharma in Boulder in 2015.

Boulder-based Array BioPharma (Nasdaq: ARRY) has spun out a new entity to research and develop drugs for rare diseases, according to documents filed with the U.S. Securities and Exchange Commission on Friday and first reported by finance news site Seeking Alpha.

SEC filings show Array, which developed targeted drugs for cancer treatment, gave rights and assets from its ARRY-797 drug program to a wholly owned subsidiary, Yarra Therapeutics. ARRY-797 is currently in Phase 2 trials for patients with a rare form of cardiomyopathy, a catch-all name for diseases of the heart muscle.

Whether Yarra will focus on additional diseases is unclear; SEC documents say only that its assets “include” the ARRY-797 program. Officials for Array were unavailable for comment.

About brandsauthority

Check Also

What’s on Tokyo Olympics at present: August 1 – Swimming, hockey, tennis, BMX, crusing, diving, athletics

Cam Smith will be looking to make a surge toward the medals in the final …

Leave a Reply

%d bloggers like this: